Immunomedics (IMMU) Misses Q4 EPS by 36c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMMU Hot Sheet
Price: $87.86 --0%
Financial Fact:
Costs of goods sold: 255.11K
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Costs of goods sold: 255.11K
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Immunomedics (NASDAQ: IMMU) reported Q4 EPS of ($0.48), $0.36 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $641 thousand versus the consensus estimate of $2.33 million.
For earnings history and earnings-related data on Immunomedics (IMMU) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deluxe Corp. (DLX) Tops Q3 EPS by 11c; offers guidance
- Cytek Biosciences, Inc. (CTKB) Tops Q3 EPS by 1c ; Offers Guidance
- Chime Financial, Inc. (CHYM) Tops Q3 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
